RxDoctor Payments Data

Zidrieck Valdes, MD

Internal Medicine · Las Vegas, NVNPI 1851339360

Payments from drug & device makers

$476in general payments, 2019–2025

Across 11 payments — averaging $43.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$135
  • IBSA Pharma Inc.$124
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$70
  • Mannkind Corporation$43
  • Lundbeck LLC$35
  • MDD US Operations, LLC$22
  • plus $48 from 3 others

What the payments were for

  • Food & beverage$43391%
  • Education$439%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$476 in reported general payments places this provider in the 60th percentile of 1,071 internal medicine providers in Nevada.

See all internal medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$301,993
Medicare patients
191
Services billed
7,023

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega HafyeraPaliperidone Palmitate11$233,199
NuplazidPimavanserin Tartrate25$61,605
EliquisApixaban89$24,085
RexultiBrexpiprazole22$14,689
OzempicSemaglutide11$9,121
XareltoRivaroxaban19$5,570
Sevelamer Carbonate22$3,432
Megestrol Acetate37$2,965
Rivastigmine12$2,864
Donepezil Hcl132$2,353
Memantine Hcl85$2,275
Enoxaparin Sodium32$2,139
Atorvastatin Calcium176$1,767
AmantadineAmantadine Hcl22$1,494
Pantoprazole Sodium81$1,481

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$17$61,60525 claims
Otsuka America Pharmaceutical, Inc.Rexulti$135$14,68922 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,071 internal medicine providers in Nevada.

Other internal medicine in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →